95 related articles for article (PubMed ID: 2509004)
1. [Interferon-gamma (IFN) induced by purified hepatitis B surface antigen (HBSAG) in HBV vaccines].
Fei GZ
Zhonghua Yi Xue Za Zhi; 1989 May; 69(5):271-3, 18. PubMed ID: 2509004
[TBL] [Abstract][Full Text] [Related]
2. Humoral and cellular immune responses to hepatitis B vaccination in hepatitis B surface antigen-carrier children who cleared serum-hepatitis B surface antigen.
Hsu HY; Chang MH; Hsieh RP; Ni YH; Chi WK
Hepatology; 1996 Dec; 24(6):1355-60. PubMed ID: 8938161
[TBL] [Abstract][Full Text] [Related]
3. Kinetics of hepatitis B surface antigen-specific immune responses in acute and chronic hepatitis B or after HBs vaccination: stimulation of the in vitro antibody response by interferon gamma.
Böcher WO; Herzog-Hauff S; Schlaak J; Meyer zum Büschenfeld KH; Löhr HF
Hepatology; 1999 Jan; 29(1):238-44. PubMed ID: 9862872
[TBL] [Abstract][Full Text] [Related]
4. [Cellular immune responses of recombinant hepatitis B (rHB) vaccine and HBsAG derived from Hansenula polymorpha cells].
Hu ZY; He P; Zhang R; Fang X; Zhu FC; Qiu SH; Li HM; Wang H; Liang ZL; Zhuang H
Zhonghua Liu Xing Bing Xue Za Zhi; 2008 Jul; 29(7):706-11. PubMed ID: 19031766
[TBL] [Abstract][Full Text] [Related]
5. Interferon-gamma (IFN-gamma) response to different hepatitis B virus antigens in hepatitis B virus infection.
Paul S; Tabassum S; Islam MN
Bangladesh Med Res Counc Bull; 2004 Aug; 30(2):71-7. PubMed ID: 15813485
[TBL] [Abstract][Full Text] [Related]
6. Reduced hepatitis B virus surface antigen-specific Th1 helper cell frequency of chronic HBV carriers is associated with a failure to produce antigen-specific antibodies in the trimera mouse.
Böcher WO; Galun E; Marcus H; Daudi N; Terkieltaub D; Shouval D; Löhr HF; Reisner Y
Hepatology; 2000 Feb; 31(2):480-7. PubMed ID: 10655274
[TBL] [Abstract][Full Text] [Related]
7. Inducing oral immune regulation of hepatitis B virus envelope proteins suppresses the growth of hepatocellular carcinoma in mice.
Gotsman I; Alper R; Klein A; Rabbani E; Engelhardt D; Ilan Y
Cancer; 2002 Jan; 94(2):406-14. PubMed ID: 11900226
[TBL] [Abstract][Full Text] [Related]
8. Improved cell mediated immune responses after successful re-vaccination of non-responders to the hepatitis B virus surface antigen (HBsAg) vaccine using the combined hepatitis A and B vaccine.
Nyström J; Cardell K; Björnsdottir TB; Fryden A; Hultgren C; Sällberg M
Vaccine; 2008 Nov; 26(47):5967-72. PubMed ID: 18804140
[TBL] [Abstract][Full Text] [Related]
9. Humoral and cellular immune responses to a hepatitis B vaccine booster 15-18 years after neonatal immunization.
Lu CY; Ni YH; Chiang BL; Chen PJ; Chang MH; Chang LY; Su IJ; Kuo HS; Huang LM; Chen DS; Lee CY
J Infect Dis; 2008 May; 197(10):1419-26. PubMed ID: 18444799
[TBL] [Abstract][Full Text] [Related]
10. In vitro anti-HBs antibody synthesis from anti-hepatitis B vaccine recipients.
Barnaba V; Levrero M; Ruberti G; van Dyke A; Perrone A; Musca A; Balsano F
Clin Exp Immunol; 1987 Nov; 70(2):283-8. PubMed ID: 2962789
[TBL] [Abstract][Full Text] [Related]
11. Hepatitis B surface antigen-specific T and B cell memory in individuals who had lost protective antibodies after hepatitis B vaccination.
Bauer T; Jilg W
Vaccine; 2006 Jan; 24(5):572-7. PubMed ID: 16171909
[TBL] [Abstract][Full Text] [Related]
12. Partial delipidation improves the T-cell antigenicity of hepatitis B virus surface antigen.
Desombere I; Willems A; Gijbels Y; Leroux-Roels G
J Virol; 2006 Apr; 80(7):3506-14. PubMed ID: 16537618
[TBL] [Abstract][Full Text] [Related]
13. Intramuscular versus low-dose intradermal hepatitis B vaccine. Assessment by humoral and cellular immune response to hepatitis B surface antigen.
Frazer IH; Jones B; Dimitrakakis M; Mackay IR
Med J Aust; 1987 Mar; 146(5):242-5. PubMed ID: 2950303
[TBL] [Abstract][Full Text] [Related]
14. [Immune response to hepatitis B vaccine in neonates born to mothers with various infection status of hepatitis B virus].
Yin SR
Zhonghua Liu Xing Bing Xue Za Zhi; 1989 Aug; 10(4):198-202. PubMed ID: 2805044
[TBL] [Abstract][Full Text] [Related]
15. Coexistence of hepatitis B surface antigen (HBsAg) and heterologous subtype-specific antibodies to HBsAg among patients with chronic hepatitis B virus infection.
Zhang JM; Xu Y; Wang XY; Yin YK; Wu XH; Weng XH; Lu M
Clin Infect Dis; 2007 May; 44(9):1161-9. PubMed ID: 17407033
[TBL] [Abstract][Full Text] [Related]
16. Alginate coated chitosan nanoparticles are an effective subcutaneous adjuvant for hepatitis B surface antigen.
Borges O; Silva M; de Sousa A; Borchard G; Junginger HE; Cordeiro-da-Silva A
Int Immunopharmacol; 2008 Dec; 8(13-14):1773-80. PubMed ID: 18801462
[TBL] [Abstract][Full Text] [Related]
17. Vaccination against hepatitis B in liver transplant recipients: pilot analysis of cellular immune response shows evidence of HBsAg-specific regulatory T cells.
Bauer T; Günther M; Bienzle U; Neuhaus R; Jilg W
Liver Transpl; 2007 Mar; 13(3):434-42. PubMed ID: 17318860
[TBL] [Abstract][Full Text] [Related]
18. Role of hepatitis B virus in non-B, non-C chronic liver disease: in vitro proliferation and interferon-gamma production of peripheral blood mononuclear cells in response to hepatitis B core antigen and its relation to hepatitis activity.
Niigaki M; Fukuda R; Hamamoto S; Ishimura N; Ishihara S; Akagi S; Watanabe M; Kinoshita Y
Am J Gastroenterol; 2000 Jan; 95(1):239-47. PubMed ID: 10638591
[TBL] [Abstract][Full Text] [Related]
19. Breaking tolerance leads to autoantibody production but not autoimmune liver disease in hepatitis B virus envelope transgenic mice.
Wirth S; Guidotti LG; Ando K; Schlicht HJ; Chisari FV
J Immunol; 1995 Mar; 154(5):2504-15. PubMed ID: 7868916
[TBL] [Abstract][Full Text] [Related]
20. Two decades of universal hepatitis B vaccination in taiwan: impact and implication for future strategies.
Ni YH; Huang LM; Chang MH; Yen CJ; Lu CY; You SL; Kao JH; Lin YC; Chen HL; Hsu HY; Chen DS
Gastroenterology; 2007 Apr; 132(4):1287-93. PubMed ID: 17433322
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
